A study led by researchers in the University of Florida College of Pharmacy has found that a pair of popular glucose-lowering medications may have protective effects against the development of ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

Weight-reducing diabetes medications, specifically SGLT2 inhibitors and GLP-1 receptor agonists, may increase fall risk in type 2 diabetes patients due to potential muscle mass loss.

A new drug, called orforglipron, can help people with diabetes manage their A1C and weight, according to topline results from ...

Drugmaker Eli Lilly said that in Phase 3 studies of over 550 adults, their oral GLP-1 pill, orforglipron, could reduce ...

Type 2 diabetes medications include metformin, sulfonylureas, alpha-glucosidase inhibitors, and other medications that change ...

A daily pill from drugmaker Eli Lilly has shown safety results comparable to the leading injectable GLP-1 drugs Mounjaro and ...

Tirzepatide is approved for 3 indications in the US: type 2 diabetes, chronic weight management, and obstructive sleep apnea.

The injectable prescription medicine is primarily used to treat type 2 diabetes. Fetterman was prescribed the medication in July 2024. "As a stroke survivor, I was interested in studies showing ...

The drug helped lower patients’ blood sugar and reduce their weight by an average of 16 pounds.

Hypoglycemia occurs when levels of blood sugar, or glucose, fall too low; a reading below 70 milligrams per deciliter is an ...